ZBTB22 Inhibitors
Chemical inhibitors of ZBTB22 can modulate its function by interfering with various signaling pathways that ZBTB22 is known to influence. Peimine targets the nuclear factor kappa B (NF-κB) signaling pathway, which is a pivotal point for ZBTB22 in regulating immune response and inflammation. By inhibiting NF-κB, Peimine can reduce the functional activity of ZBTB22 in the immune system. Similarly, Curcumin interacts with the JAK/STAT signaling pathway, another crucial cascade for ZBTB22's role in modulating gene transcription. The suppression of JAK/STAT by Curcumin limits ZBTB22's ability to influence this pathway's gene expression. PD98059, U0126, and SL327 are inhibitors that focus on the MAPK/ERK pathway, affecting ZBTB22's capacity to regulate cell cycle genes and hence impede its role in cell proliferation and survival. LY294002 and Wortmannin exert their effects through the inhibition of the PI3K/Akt pathway, which can result in the reduction of ZBTB22's regulatory effects on cellular homeostasis and survival due to their action on cell survival and metabolism.
In addition, SP600125 and Kenpaullone represent compounds that inhibit the JNK and GSK-3β signaling pathways, respectively. SP600125's inhibition of JNK can affect ZBTB22's involvement in apoptosis and cell differentiation, while Kenpaullone's targeting of GSK-3β can lead to a decrease in ZBTB22's function in cell cycle regulation. SB203580 and PD169316, both p38 MAPK inhibitors, disrupt the inflammatory response and stress signaling pathways, leading to a diminution of ZBTB22's regulatory capacity in these contexts. Lastly, Rapamycin's inhibition of mTOR is significant because it can limit ZBTB22's role in cellular growth and stress responses, thus impacting the protein's overall regulatory functions. Each of these chemicals, by targeting specific pathways, can alter the functional dynamics of ZBTB22, resulting in a wide-ranging influence across different cellular processes that ZBTB22 is known to affect.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin is known to inhibit the JAK/STAT signaling pathway, a pathway in which ZBTB22 plays a role by modulating the transcriptional activity of certain genes. Inhibition of JAK/STAT by Curcumin can therefore reduce the functional influence of ZBTB22 on this pathway's target gene expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of the MAPK/ERK pathway, which is involved in cell proliferation and survival. ZBTB22 has been associated with the regulation of cell cycle genes and by inhibiting the MAPK/ERK pathway, PD98059 can inhibit ZBTB22's ability to affect cell cycle progression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits the PI3K/Akt pathway, which has implications in cell survival and metabolism. Since ZBTB22 has a role in cellular stress responses, inhibiting PI3K/Akt can impede ZBTB22's regulatory effects on cellular homeostasis and survival. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the JNK signaling pathway, which is implicated in apoptosis and cell differentiation. ZBTB22's involvement in gene expression related to these cellular processes means that JNK inhibition by SP600125 can inhibit the functional activity of ZBTB22. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK, a pathway involved in inflammatory responses and stress. By inhibiting p38 MAPK, SB203580 can hinder ZBTB22's ability to regulate genes involved in the stress response and inflammation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream regulators of the ERK pathway. As ZBTB22 can impact the cell cycle and differentiation, inhibition of MEK by U0126 can lead to reduced ZBTB22-mediated transcriptional regulation of these processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor that affects various signaling pathways, including those regulating cell growth and survival. By inhibiting PI3K, Wortmannin can decrease the regulatory influence of ZBTB22 on cell survival pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a central protein in regulating cell growth and metabolism. ZBTB22's role in cellular growth and stress responses can be reduced by Rapamycin's inhibition of mTOR activity. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $60.00 $150.00 $226.00 $495.00 | 1 | |
Kenpaullone is a known inhibitor of GSK-3β, a kinase involved in numerous cellular functions including cell cycle regulation. With ZBTB22's implication in gene regulation during the cell cycle, GSK-3β inhibition by Kenpaullone can lead to diminished ZBTB22 function in these processes. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $86.00 $153.00 $275.00 $452.00 | 3 | |
PD169316 is an inhibitor of p38 MAPK, which like SB203580, targets the inflammatory response and stress signaling pathways. Inhibition of p38 MAPK by PD169316 can lead to a decrease in ZBTB22's regulatory capacity in these pathways. | ||||||